|
OALib Journal期刊
ISSN: 2333-9721
费用：99美元
|
|
|
|
先导化合物结构优化策略(二)——结构修饰降低潜在毒性
, PP. 1-15
Keywords: 药物毒性,警惕结构,药物特质性毒性反应,cyp450,优化策略
Abstract:
药物特质性毒性反应能够引发严重的药物毒副作用甚至危及患者生命。含有警惕结构的药物在体内能够产生活性代谢物，这是药物发生特质性毒性反应的一个重要原因。优化药物分子中的警惕结构以及通过结构改造避免警惕结构产生活性代谢物，是药物早期研发中降低药物毒性风险的重要手段。本文通过比对上市与撤市药物，运用实例阐述降低药物毒性风险的结构改造策略，包括封闭代谢位点、改变代谢途径、降低警惕结构反应性、生物电子等排以及前药等。
| [1] | lasserke,allenpd,woolhandlersj,etal.timingofnewblackboxwarningsandwithdrawalsforprescriptionmedications[j].jammedass,2002,287:2215-2220.
|
| [2] | nassaraef,kamelam,clarimontc.improvingthedecision-makingprocessinstructuralmodificationofdrugcandidates[j].drugdiscovtoday,2004,9:1055-1064.
|
| [3] | fieserlf.carcinogenicactivity,structure,andchemicalreactivityofpolynucleararomatichydrocarbons[j].amjcancer,1938,34:37-124.
|
| [4] | kalgutkaras,sogliajr.minimizingthepotentialformetabolicactivationindrugdiscovery[j].expertopindrugmetabtoxicol,2005,1:91-142.
|
| [5] | matzingerp.thedangermodel:arenewedsenseofself[j].science,2002,296:301-305.
|
| [6] | pumfordnr,halmesnc.proteintargetsofxenobioticreactiveintermediates[j].annurevpharmacoltoxicol,1997,37:91-117.
|
| [7] | yuanl,kaplowitzn.glutathioneinliverdiseasesandhepatotoxicity[j].molaspectsmed,2009,30:29-41.
|
| [8] | jollowdj,mitchelljr,potterwz,etal.acetaminophen-inducedhepaticnecrosis.2.roleofcovalentbindinginvivo[j].jpharmacolexpther,1973,187:195-202.
|
| [9] | jollowdj,thorgeirssonss,potterwz,etal.acetaminophen-inducedhepaticnecrosis.6.metabolicdispositionoftoxicandnontoxicdosesofacetaminophen[j].pharmacology,1974,12:251-271.
|
| [10] | prescottlf.3rdlillyprizelecture.universityoflondon,january,1979.thenephrotoxicityandhepatotoxicityofantipyreticanalgesics[j].brjclinpharmacol,1979,7:453-462.
|
| [11] | wirthpj,dybinge,vonbahrc,etal.mechanismofn-hydroxyacetylarylaminemutagenicityinthesalmonellatestsystem-metabolic-activationofn-hydroxyphenacetinbyliverandkidneyfractionsfromrat,mouse,hamster,andman[j].currmolpharmacol,1980,18:117-127.
|
| [12] | keeseyj,beinm,minkj,etal.chestradiography,tomography,andcomputedtomographyfordetectionofthymomainmyasthenia-gravis[j].neurology,1978,28:371.
|
| [13] | neftelka,woodtlyw,schmidm,etal.amodiaquineinducedagranulocytosisandliver-damage[j].brmedj,1986,292:721-723.
|
| [14] | o'neillpm,shoneae,stanfordd,etal.synthesis,antimalarialactivity,andpreclinicalpharmacologyofanovelseriesof4'-fluoroand4'-chloroanaloguesofamodiaquine.identificationofasuitable"back-up"compoundforn-tert-butylisoquine[j].jmedchem,2009,52:1828-1844.
|
| [15] | kassahunk,pearsonpg,tangw,etal.studiesonthemetabolismoftroglitazonetoreactiveintermediatesinvitroandinvivo.evidencefornovelbiotransformationpathwaysinvolvingquinonemethideformationandthiazolidinedioneringscission[j].chemrestoxicol,2001,14:62-70.
|
| [16] | kalgutkaras,vazand,lameme,etal.bioactivationofthenontricyclicantidepressantnefazodonetoareactivequinone-iminespeciesinhumanlivermicrosomesandrecombinantcytochromep4503a4[j].drugmetabdispos,2005,33:243-253.
|
| [17] | stepanaf,walkerdp,baumanj,etal.structuralalert/reactivemetaboliteconceptasappliedinmedicinalchemistrytomitigatetheriskofidiosyncraticdrugtoxicity:aperspectivebasedonthecriticalexaminationoftrendsinthetop200drugsmarketedintheunitedstates[j].chemrestoxicol,2011,24:1345-1410.
|
| [18] | obachrs,kalgutkaras,rydertf,etal.invitrometabolismandcovalentbindingofenol-carboxamidederivativesandanti-inflammatoryagentssudoxicamandmeloxicam:insightsintothehepatotoxicityofsudoxicam[j].chemrestoxicol,2008,21:1890-1899.
|
| [19] | adusumallive,choiym,romanyshynla,etal.isolationandidentificationof3-carbamoyloxy-2-phenylpropionicacidasamajorhumanurinarymetaboliteoffelbamate[j].drugmetabdispos,1993,21:710-716.
|
| [20] | roeckleinba,sackshj,mortkoh,etal.fluorofelbamate[j].neurotherapeutics,2007,4:97-101.
|
| [21] | smithks,smithpl,headytn,etal.invitrometabolismoftolcaponetoreactiveintermediates:relevancetotolcaponelivertoxicity[j].chemrestoxicol,2003,16:123-128.
|
| [22] | wikbergt,vuorelaa,ottoilap,etal.identificationofmajormetabolitesofthecatechol-o-methyltransferaseinhibitorentacaponeinratsandhumans[j].drugmetabdispos,1993,21:81-92.
|
| [23] | fromentyb,pessayred.inhibitionofmitochondrialbeta-oxidationasamechanismofhepatotoxicity[j].alimentpharmacolther,1995,67:101-154.
|
| [24] | hessda,sissonme,suriah,etal.cytotoxicityofsulfonamidereactivemetabolites:apoptosisandselectivetoxicityofcd8(+)cellsbythehydroxylamineofsulfamethoxazole[j].fasebj,1999,13:1688-1698.
|
| [25] | xujj,diazd,o'brienpj.applicationsofcytotoxicityassaysandpre-lethalmechanisticassaysforassessmentofhumanhepatotoxicitypotential[j].chembiolinteract,2004,150:115-128.
|
| [26] | baumanjn,frederickks,sawanta,etal.comparisonofthebioactivationpotentialoftheantidepressantandhepatotoxinnefazodonewitharipiprazole,astructuralanalogandmarketeddrug[j].drugmetabdispos,2008,36:1016-1029.
|
| [27] | damstenmc,devliegerjsb,niessenwma,etal.trimethoprim:novelreactiveintermediatesandbioactivationpathwaysbycytochromep450s[j].chemrestoxicol,2008,21:2181-2187.
|
| [28] | lixh,kameneckatm,cameronmd.bioactivationoftheepidermalgrowthfactorreceptorinhibitorgefitinib:implicationsforpulmonaryandhepatictoxicities[j].chemrestoxicol,2009,22:1736-1742.
|
| [29] | wangj,davism,lif,etal.anovelapproachforpredictingacylglucuronidereactivityviaschiffbaseformation:developmentofrapidlyformedpeptideadductsforlc/ms/msmeasurements[j].chemrestoxicol,2004,17:1206-1216.
|
| [30] | walkergs,athertonj,baumanj,etal.determinationofdegradationpathwaysandkineticsofacylglucuronidesbynmrspectroscopy[j].chemrestoxicol,2007,20:876-886.
|
| [31] | babaa,yoshiokat.structure-activityrelationshipsforthedegradationreactionof1-beta-o-acylglucuronides.part3:electronicandstericdescriptorspredictingthereactivityofaralkylcarboxylicacid1-beta-o-acylglucuronides[j].chemrestoxicol,2009,22:1998-2008.
|
| [32] | tadaoy,akikob.structure-activityrelationshipsforthedegradationreactionof1-β-o-acylglucuronides.part2:electronicandstericdescriptorspredictingthereactivityof1-β-o-acylglucuronidesderivedfrombenzoicacids[j].chemrestoxicol,2009,22:1559-1569.
|
| [33] | lloyds,haydenmj,sakaiy,etal.differentialinvitrohepatotoxicityoftroglitazoneandrosiglitazoneamongcryopreservedhumanhepatocytesfrom37donors[j].chembiolinteract,2002,142:57-71.
|
| [34] | bonierbalee,valadonp,ponsc,etal.oppositebehaviorsofreactivemetabolitesoftienilicacidanditsisomertowardliverproteins:useofspecificanti-tienilicacid-proteinadductantibodiesandthepossiblerelationshipwithdifferenthepatotoxiceffectsofthetwocompounds[j].chemrestoxicol,1999,12:286-296.
|
| [35] | dansettepm,berthog,mansuyd.firstevidencethatcytochromep450maycatalyzeboths-oxidationandepoxidationofthiophenederivatives[j].biochembiophysrescommun,2005,338:450-455.
|
| [36] | o'donnelljp,dalviedk,kalgutkaras,etal.mechanism-basedinactivationofhumanrecombinantp4502c9bythenonsteroidalanti-inflammatorydrugsuprofen[j].drugmetabdispos,2003,31:1369-1377.
|
| [37] | shanj,zhangb,zhuy,etal.overcomingclopidogrelresistance:discoveryofvicagrelasahighlypotentandorallybioavailableantiplateletagent[j].jmedchem,2012,55:3342-3352.
|
| [38] | foxkaa.acutecoronarysyndromesin2010:progressfromtrialstopractice[j].natrevcardiol,2011,8:68-70.
|
| [39] | liuzc,uetrechtjp.clozapineisoxidizedbyactivatedhumanneutrophilstoareactivenitreniumionthatirreversiblybindstothecells[j].jpharmacolexpther,1995,275:1476-1483.
|
| [40] | uetrechtj,zahidn,tehima,etal.structuralfeaturesassociatedwithreactivemetaboliteformationinclozapineanalogues[j].chembiolinteract,1997,104:117-129.
|
| [41] | cravedijp,perdudurande,baradatm,etal.chloramphenicoloxamylethanolamineasanend-productofchloramphenicolmetabolisminratandhumans:evidencefortheformationofaphospholipidadduct[j].chemrestoxicol,1995,8:642-648.
|
| [42] | notleylm,dewolfcjf,wunschrm,etal.bioactivationoftamoxifenbyrecombinanthumancytochromep450enzymes[j].chemrestoxicol,2002,15:614-622.
|
| [43] | boelsterliua,hohk,zhousf,etal.bioactivationandhepatotoxicityofnitroaromaticdrugs[j].currdrugmetab,2006,7:715-727.
|
| [44] | yangm,chordiamd,lifp,etal.neutrophil-andmyeloperoxidase-mediatedmetabolismofreducednimesulide:evidenceforbioactivation[j].chemrestoxicol,2010,23:1691-1700.
|
| [45] | jean-françoisr,deniza,nancyg,etal.analoguesofnimesulide:design,synthesis,andinvitroandinvivopharmacologicalevaluationaspromisingcyclooxygenase1and2inhibitors[j].jmedchem,2009,52:5864-5871.
|
| [46] | uetrechtj.predictionofanewdrug'spotentialtocauseidiosyncraticreactions[j].curropindrugdiscovdev,2001,4:55-59.
|
| [47] | walgrenjl,mitchellmd,thompsondc.roleofmetabolismindrug-inducedidiosyncratichepatotoxicity[j].critrevtoxicol,2005,35:325-361.
|
Full-Text
|
|
Contact Us
service@oalib.com QQ:3279437679 
WhatsApp +8615387084133
|
|
